SIREN : 389099300
BIOGENE is a French company founded 33 years ago, specialized in the sector Activités des sociétés holding. Based in TROYES (10000), this company of category PME shows in 2024 a revenue of 22 k€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-05-02
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicador | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Ingresos | 22 051 € | 51 598 € | 299 125 € | 72 419 € | 29 407 € | 6 000 € | 6 000 € | 6 000 € |
| Resultado neto | -1 626 € | 200 021 € | 139 823 € | 46 918 € | 47 149 € | 87 710 € | 29 559 € | 3 485 € |
| EBITDA | -3 793 € | 35 167 € | 113 908 € | 59 480 € | 25 061 € | 3 928 € | 3 624 € | 4 760 € |
| Margen neto | -7.4% | 387.7% | 46.7% | 64.8% | 160.3% | 1461.8% | 492.6% | 58.1% |
In 2024, BIOGENE achieves revenue of 22 k€. Over the period 2016-2024, the company shows strong growth with a CAGR (compound annual growth rate) of +17.7%. Significant drop of -57% vs 2023. After deducting consumption (-176 k€), gross margin stands at 198 k€, i.e. a rate of 899%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches -4 k€, representing -17.2% of revenue. Warning negative scissor effect: despite revenue change (-57%), EBITDA varies by -111%, reducing margin by 85.4 pts. This reflects costs rising faster than revenue. Negative EBITDA means operations do not cover current expenses: concerning situation. Net income is negative at -2 k€ (-7.4% of revenue), which will impact equity.
22 051 €
198 266 €
-3 793 €
-7 123 €
-1 626 €
-17.2%
The debt ratio (= Financial debt / Equity x 100) stands at 25%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 80%. This high autonomy means the company finances most of its assets through equity, a sign of strength. Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 56.1 years of cash flow to repay all financial debt. Beyond 7 years, banks generally consider credit risk as high. Cash flow represents 7.7% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment. Satisfactory level allowing partial financing of growth.
25.115%
79.546%
7.718%
56.143
48.7%
In 2024, the debt ratio of BIOGENE (25.11) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.
In 2024, the financial autonomy of BIOGENE (79.5%) ranks above the median of the sector. This ratio represents the share of equity in total financing. This comfortable position offers an appreciable safety margin.
In 2024, the repayment capacity of BIOGENE (56.14) ranks above the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A reduction effort could improve financial strength.
The liquidity ratio (= Current assets / Current liabilities) stands at 20432.76. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
20432.762
-149.512
In 2024, the liquidity ratio of BIOGENE (20432.76) ranks in the top 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio above 1 ensures comfortable coverage of short-term maturities.
In 2024, the interest coverage of BIOGENE (-149.5x) ranks below the median of the sector. This ratio indicates how many times operating income covers interest expenses. An improvement would strengthen the competitive position.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 0 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 3 days. Favorable situation: supplier credit is longer than customer credit by 3 days. Inventory turnover is 5529 days (= Average inventory / Cost of goods x 360). This high level ties up cash and potentially creates obsolescence risk. Overall, WCR represents 5641 days of revenue, i.e. 346 k€ to permanently finance. Over 2016-2024, WCR increased by +55833%, requiring additional financing.
345 534 €
0 j
3 j
5529 j
5641 j
Based on 54 transactions of similar company sales
in 2024,
the value of BIOGENE is estimated at
12 983 €
(range 8 077€ - 15 434€).
The price/revenue ratio is 0.59x
(in line with sector norms).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Medium reliability: estimate to be confirmed with in-depth analysis.
Only this financial indicator is available for this company.
This estimate is based on the analysis of 54 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Compare BIOGENE with other companies in the same sector:
Voir toutes les statistiques du secteur Activités des sociétés holding
The revenue of BIOGENE in 2024 is 22 k€.
BIOGENE recorded a net loss in 2024.
The headquarters of BIOGENE is located in TROYES (10000), in the department Aube.
The tax return of BIOGENE is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
BIOGENE operates in the sector Activités des sociétés holding (NAF code 64.20Z). See the 'Sector positioning' section above to compare the company with its competitors.